Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial to Evaluate the Optimal Number of Passes Required for Molecular Profiling During Endoscopic Ultrasound-guided Fine Needle Biopsy of Pancreatic Adenocarcinoma

NCT05043532 is registered in ClinicalTrials.gov with Orlando Health, Inc. as lead sponsor.

NCT NCT05043532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05043532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial to Evaluate the Optimal Number of Passes Required for Molecular Profiling During Endoscopic Ultrasound-guided Fine Needle Biopsy of Pancreatic Adenocarcinoma
Lead sponsor
Orlando Health, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
August 18, 2021
Completion date
June 30, 2023
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, pancreatic cancer, pancreatic neoplasms